FRANKFURT (Dow Jones) – Ulmer generic manufacturers ratiopharm is on the Israeli Teva Pharmaceutical Industries Ltd. sold. The world’s largest producer of generic drugs estimated the value of the transaction on Thursday in a statement with 3.625 billion euros. (Photo: Ratiopharm)
After approval by the antitrust Teva intends to Acquisition of ratiopharm GmbH have completed by year end.
Together, the two generic companies came last Year on a turnover of 16.2 billion USD, of which 5.2 billion USD in Europe. In the course of integrating the two companies want to Teva of three Years distributed leverage synergies of at least 300 million euros. At the latest three quarters after completion of the purchase is the acquisition positively to Result of the Teva-help group.
Teva, based in Jerusalem was modified in 2008 by a Billion takeover hips. At the time, took over the Israeli Group’s U.S. rival Barr for 7.46 billion USD.
Seller of ratiopharm is the wealth of the VEM Early 2009, late industrialist Adolf Merckle. Merckle was under others because of false speculations, with Volkswagen shares in massive Financial distress advised. To repay debt must be now of the VEM ratiopharm separated.
Ludwig Merckle, representatives of the owner family ratiopharm, on Thursday called the sale a "painful Step. "He believed that the" merger with the largest Allow generic manufacturers worldwide ratiopharm will continue to grow and be successful. "
In addition to Teva at ratiopharm were modified according to unconfirmed Reports, the Icelandic company Actavis and the U.S. pharmaceutical giant Pfizer in the race. Ratiopharm is according to its own data in 24 countries Branches represented. The group employs nearly 5600 Employees. Teva is taking the acquisition on a global Workforce of nearly 40,000 employees, about 18,000 of them in Europe.
By Rob-Ridder, Dow Jones Newswires;
+49 (0) 69 - 29725 111, unternehmen.de @ dowjones.com
DJG / rio / jhe / mrf